Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
NCT01261299
Terminated
Carboplatin kills cancer cells mainly through induction of DNA damage (drug-DNA adducts). The goal of this clinical trial is to determine if chemoresistance to carboplatin can be identified by measuring carboplatin-induced DNA monoadducts, the precursor of Pt-DNA diadducts or crosslinks, from subtherapeutic drug doses given prior to the initiation of chemotherapy. We hypothesize that low levels of carboplatin-DNA monoadducts and rapid drug-DNA adduct repair correlate with chemoresistance. A high... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2018
Locations: University of California Los Angeles, Los Angeles, California +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Urinary Bladder Neoplasms
Register for Updates
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
NCT01097057
Completed
This phase II trial is studying how well giving rituximab; ifosfamide, carboplatin, and etoposide (ICE) combination chemotherapy; and filgrastim (G-CSF) together with plerixafor works in treating patients with non-Hodgkin lymphoma undergoing mobilization of autologous peripheral blood stem cells. Giving chemotherapy (ICE) with monoclonal antibodies, such as rituximab, stops the growth of cancer cells by stopping them from dividing or by killing them and helps get better autologous stem cell prod... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/28/2017
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Non-Hodgkin Lymphoma
Register for Updates
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
NCT02130869
Completed
This is a pilot clinical trial investigating the addition of haploidentical natural killer cell infusion to autologous stem cell transplantation. This intervention will be evaluated in children with high-risk solid tumors for whom autologous transplantation is indicated. Natural killer cells from a haploidentical family member will be given after high dose chemotherapy and positively selected autologous stem cells. In patients with neuroblastoma, the anti-GD2 antibody hu14.18K322A will also be g... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
12/21/2017
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma, Lymphoma, High-risk Tumor
Register for Updates
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
NCT01188876
Completed
Pralatrexate is a type of antifolate drug which means is restrains the production of folic acid in the body. Folic acids are used by tumors to increase tumor cell growth and division. It is believed that reducing folic acid will hinder the rapid division of tumor cells, their growth and production. Carboplatin is an FDA approved chemotherapy drug for ovarian, fallopian tube and primary peritoneal cancer. Some antifolate drugs are used with other chemotherapy drugs to enhance cancer-fighting char... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/20/2017
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Register for Updates
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
NCT01237678
Terminated
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2017
Locations: Arizona Cancer Center @ UMC North, Tucson, Arizona +47 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer
NCT02172846
Completed
This phase I trial studies the side effects and best dose of hypofractionated proton beam radiation therapy when given together with paclitaxel and carboplatin in treating patients with stage II-III non-small cell lung cancer. Proton beam radiation therapy is a type of radiation therapy that uses streams of protons (tiny particles with a positive charge) to kill tumor cells. Giving proton beam radiation therapy at higher doses over fewer days (hypofractionation) may improve local control of the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2017
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00331422
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving chemotherapy drugs before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin before surgery works in treating patients with advanced ovarian epithelial canc... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/03/2017
Locations: University of Minnesota Cancer Center, Minneapolis, Minnesota
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
NCT00400803
Completed
The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2017
Locations: Hubert H. Humphrey Cancer Center, Minneapolis, Minnesota +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
NCT00258362
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving carboplatin a... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/03/2017
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota +1 locations
Conditions: Endometrial Cancer
Register for Updates
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
NCT00281827
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving carboplatin and gemcitabine together with thalidomide before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2017
Locations: University of Minnesota Cancer Center, Minneapolis, Minnesota +2 locations
Conditions: Lung Cancer
Register for Updates
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00023673
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them with specialized radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the effectiveness of radiation therapy combined with paclitaxel and carboplatin in treating patients who have stage III non... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/27/2017
Locations: Mobile Infirmary Medical Center, Mobile, Alabama +40 locations
Conditions: Lung Cancer
Register for Updates
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
NCT00755313
Completed
RATIONALE: Gathering information over time from laboratory tests, imaging scans, and assessment tests may help doctors learn more about the side effects of chemotherapy and plan the best treatment. PURPOSE: This clinical trial is studying the effects of chemotherapy on the brain in women with newly diagnosed early-stage breast cancer.
Gender:
FEMALE
Ages:
Between 35 years and 80 years
Trial Updated:
11/21/2017
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Conditions: Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Register for Updates